{"id":33108,"date":"2025-05-09T15:02:21","date_gmt":"2025-05-09T07:02:21","guid":{"rendered":"https:\/\/flcube.com\/?p=33108"},"modified":"2025-05-09T15:02:21","modified_gmt":"2025-05-09T07:02:21","slug":"takeda-reports-2-8-revenue-growth-in-fiscal-2024-driven-by-product-sales","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33108","title":{"rendered":"Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales"},"content":{"rendered":"\n<p>Japan-headquartered Takeda (<a href=\"https:\/\/www.google.com\/finance\/quote\/TAK:NYSE\">NYSE: TAK<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/4502:TYO\">TYO: 4502<\/a>) released its financial report for fiscal year 2024 (April 1, 2024 \u2013 March 31, 2025), recording total revenue of JPY 4.58 trillion (USD 30.6 billion) and core revenue of JPY 4,579.8 billion (USD 30.6 billion). This represents a 2.8% year-over-year (YOY) growth at constant exchange rates (CER). Strong performance from growth and launched products offset the impact of patent expirations, driving both revenue and core operating profit growth.<\/p>\n\n\n\n<p><strong>Product Sales and Segment Performance<\/strong><br>Product sales from six treatment areas totaled JPY 2.2 trillion (USD 14.7 billion), up 14.7% YOY.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gastroenterology<\/strong>: Revenue increased by 7% YOY, driven by Entyvio (vedolizumab) with sales of JPY 914.1 billion (+8.5%) and Eohilia (budesonide oral suspension) at JPY 5.5 billion (+2501%).<\/li>\n\n\n\n<li><strong>Rare Diseases<\/strong>: Revenue rose by 5% YOY, led by Takhzyro (lanadelumab) with JPY 223.2 billion in sales (+18.9%), Livtencity (maribavir) with JPY 33.0 billion (+64.5%), and Adzynma (apadamtase alfa) with JPY 7.1 billion (+1516%).<\/li>\n\n\n\n<li><strong>Plasma-Derived Therapies (PDT)<\/strong>: Revenue was up 9% YOY, including immunoglobulins with JPY 757.8 billion (+11.5% YoY) and albumin with JPY 141.4 billion (+1.1%).<\/li>\n\n\n\n<li><strong>Oncology<\/strong>: Revenue increased by 17% YOY, driven by fruquintinib (co-developed with HUTCHMED) with JPY 48.0 billion (+351%) and Alunbrig (brigatinib) with JPY 36.4 billion (+22.7%).<\/li>\n\n\n\n<li><strong>Vaccines<\/strong>: Revenue was up 8% YOY, primarily from Qdenga (tetravalent dengue vaccine) with JPY 35.6 billion (+259%).<\/li>\n\n\n\n<li><strong>Neuroscience<\/strong>: Revenue declined by 14% YOY.<\/li>\n<\/ul>\n\n\n\n<p><strong>Tariff Policy Impact<\/strong><br>Takeda stated that potential risks from recent U.S. and Chinese tariff policies are limited. Approximately 50% of its total revenue is derived from the U.S., with imported goods (mainly from Europe\/Japan\/Singapore) accounting for 8\u201310% of U.S. revenue. About 4% of total revenue comes from China, with imports (from the U.S.) representing 12\u201315% of China revenue.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33109,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,874,345,1141],"class_list":["post-33108","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-nyse-tak","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April 1, 2024 \u2013 March 31, 2025), recording total revenue of JPY 4.58 trillion (USD 30.6 billion) and core revenue of JPY 4,579.8 billion (USD 30.6 billion). This represents a 2.8% year-over-year (YOY) growth at constant exchange rates (CER). Strong performance from growth and launched products offset the impact of patent expirations, driving both revenue and core operating profit growth.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33108\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales\" \/>\n<meta property=\"og:description\" content=\"Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April 1, 2024 \u2013 March 31, 2025), recording total revenue of JPY 4.58 trillion (USD 30.6 billion) and core revenue of JPY 4,579.8 billion (USD 30.6 billion). This represents a 2.8% year-over-year (YOY) growth at constant exchange rates (CER). Strong performance from growth and launched products offset the impact of patent expirations, driving both revenue and core operating profit growth.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33108\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-09T07:02:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0913.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33108#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33108\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales\",\"datePublished\":\"2025-05-09T07:02:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33108\"},\"wordCount\":260,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33108#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0913.webp\",\"keywords\":[\"Finanical Reports\",\"NYSE: TAK\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33108#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33108\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33108\",\"name\":\"Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33108#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33108#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0913.webp\",\"datePublished\":\"2025-05-09T07:02:21+00:00\",\"description\":\"Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April 1, 2024 \u2013 March 31, 2025), recording total revenue of JPY 4.58 trillion (USD 30.6 billion) and core revenue of JPY 4,579.8 billion (USD 30.6 billion). This represents a 2.8% year-over-year (YOY) growth at constant exchange rates (CER). Strong performance from growth and launched products offset the impact of patent expirations, driving both revenue and core operating profit growth.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33108#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33108\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33108#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0913.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0913.webp\",\"width\":1080,\"height\":608,\"caption\":\"Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33108#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales - Insight, China&#039;s Pharmaceutical Industry","description":"Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April 1, 2024 \u2013 March 31, 2025), recording total revenue of JPY 4.58 trillion (USD 30.6 billion) and core revenue of JPY 4,579.8 billion (USD 30.6 billion). This represents a 2.8% year-over-year (YOY) growth at constant exchange rates (CER). Strong performance from growth and launched products offset the impact of patent expirations, driving both revenue and core operating profit growth.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33108","og_locale":"en_US","og_type":"article","og_title":"Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales","og_description":"Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April 1, 2024 \u2013 March 31, 2025), recording total revenue of JPY 4.58 trillion (USD 30.6 billion) and core revenue of JPY 4,579.8 billion (USD 30.6 billion). This represents a 2.8% year-over-year (YOY) growth at constant exchange rates (CER). Strong performance from growth and launched products offset the impact of patent expirations, driving both revenue and core operating profit growth.","og_url":"https:\/\/flcube.com\/?p=33108","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-09T07:02:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0913.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33108#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33108"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales","datePublished":"2025-05-09T07:02:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33108"},"wordCount":260,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33108#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0913.webp","keywords":["Finanical Reports","NYSE: TAK","Takeda","TYO: 4502"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33108#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33108","url":"https:\/\/flcube.com\/?p=33108","name":"Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33108#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33108#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0913.webp","datePublished":"2025-05-09T07:02:21+00:00","description":"Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April 1, 2024 \u2013 March 31, 2025), recording total revenue of JPY 4.58 trillion (USD 30.6 billion) and core revenue of JPY 4,579.8 billion (USD 30.6 billion). This represents a 2.8% year-over-year (YOY) growth at constant exchange rates (CER). Strong performance from growth and launched products offset the impact of patent expirations, driving both revenue and core operating profit growth.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33108#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33108"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33108#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0913.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0913.webp","width":1080,"height":608,"caption":"Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33108#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0913.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33108"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33108\/revisions"}],"predecessor-version":[{"id":33110,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33108\/revisions\/33110"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33109"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}